The QualityStocks Daily Wednesday, July 21st, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(NURO) $10.0400 +207.98%

QualityStocks(TVPC) $0.2800 +27.27%

SmallCapRelations(SNWR) $0.0099 +26.92%

The QualityStocks Daily Stock List

KBS Fashion Group (KBSF)

StockMarketWatch, TraderPower, TradersPro, Promotion Stock Secrets, Penny Stock Titans, Monster Alerts, MarketClub Analysis, StockGuru, Fortune Stock Alerts, BUYINS.NET, Stock Guru, ProTrader, PennyPickAlerts, OTCBB Journal and Broad Street reported earlier on KBS Fashion Group (KBSF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Shishi, China and was incorporated in 2012, on January 26th by Anna Polemis. It operates as part of the consumer discretionary products industry, in the consumer discretionary sector, under the apparel and textile products sub-industry and serves consumers in China.

The company operates through the original equipment manufacturer, corporate stores and distributor network segments. The OEM segment is made up of products that are manufactured by the firm but designed by consumers while the distributor network segment comprises of sub- or direct distributors which are operated by the company’s branded stores. On the other hand, the corporate segment is focused on operating and owning corporate stores.

The enterprise provides apparel products which include trousers, jeans, t-shirts, shirts, suits, sweaters, down and cotton jackets and accessories, like caps, socks, belts, bags, shoes and footwear for males aged between 20 and 40. In addition to this, it also offers packaged group tour services online and is involved in the offline wholesale of household, pet-related, child and maternal, cosmetics, personal care and health care products.

The firm recently formed an Environmental, Social and Governance Committee which will focus on the company’s relationship with consumers, suppliers, employees and the communities it operates in, as well as its performance and governance. This move will help bring in more investors into the firm as it shows dedication and seriousness towards minimizing the effects of their operations on the environment, especially with regard to the company’s carbon footprint.

KBS Fashion Group (KBSF), closed Wednesday’s trading session at $3.95, up 0.765306%, on 94,531 volume. The average volume for the last 3 months is 408,451 and the stock's 52-week low/high is $1.64999997/$5.82999992.

Bit Brother (BTB)

We reported earlier on Bit Brother (BTB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Changsha, the People’s Republic of China and was incorporated in 2011, on November 28th. Prior to its name change in May 2021, the firm was known as Urban Tea Inc. It operates as part of the consumer staple products industry, under the consumer staples sector, in the beverages sub-industry.

The company, which is also involved in the specialty tea product retail and distribution business, markets its products through wholly owned subsidiaries. It provides pastries which include frosting cakes, freshly baked cakes and freshly baked bread; light meals like burritos, steak, pasta, sandwiches and salads, as well as other healthy options and tea-based beverages, which include milk cap tea, fruit tea and fresh milk tea, among others. The enterprise also produces para-chlorotoulene (PCT), ortho-chlorotoluene (OCT) and unsaturated polyester resin (UPR) products. UPR products can be used in manufacturing materials for trains, cars, aircrafts and vessels. Its organic compounds are used in the food additive, clean energy, coating-printing, ceramics, aerospace, dye and pigments, agrochemical, pharmaceutical and automotive industries.

The enterprise plans to acquire a share of Angelo’s Pizza 1697 Inc., which has been around for over a century. This move will have a positive effect on the growth of both companies and allow Bit Brother to actualize its plans to expand into a restaurant while it continues to grow its Bitcoin payment business.

Bit Brother (BTB), closed Wednesday’s trading session at $0.9204, off by 2.0851%, on 4,217,787 volume. The average volume for the last 3 months is 1.718M and the stock's 52-week low/high is $0.85799998/$6.69239997.

Baosheng Media Group Holdings (BAOS)

Trades Of The Day and MarketBeat reported earlier on Baosheng Media Group Holdings (BAOS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2014 by Wenxiu Zhong. It operates as part of the media industry, in the communications sector, under the advertising and marketing sub-industry and serves consumers in China.

The company provides 2 types of advertising services: Non-search engine marketing services and Search engine marketing services. Non-search engine services include in-feed advertising, social media marketing and mobile app advertising by deploying ads on mobile apps, news portals, short-video platforms and social media platforms. On the other hand, search engine marketing services involve deploying ranked search ads and other display search ads provided by search engine operators.

The enterprise connects online media and advertisers and helps them manage their online marketing activities in different ways, which include administrating and fine-tuning the ad placement process, providing ad optimization services, and advising on advertising strategies and choices as well as budgets of advertising channels. It also serves media businesses by engaging in promotion and marketing activities aimed at inducing and educating advertisers to use online advertisements, facilitating payment arrangements with advertisers and identifying advertisers to purchase their ad inventory.

The company recently entered into a securities purchase agreement with Ebang International for a $10 million investment. It plans to use these proceeds for cryptocurrency-associated business and blockchain-based marketing activities, with its CEO noting that the agreement would provide the company with technology support to apply blockchain in digital marketing. Given Ebang’s extensive industry experience, the move will not only be helpful to the firm’s marketing but also bring in more consumers and investors, which will be good for the company’s growth.

Baosheng Media Group Holdings (BAOS), closed Wednesday’s trading session at $2.66, up 7.6923%, on 262,457 volume. The average volume for the last 3 months is 490,025 and the stock's 52-week low/high is $2.3499999/$10.1999998.

Brickell Biotech (BBI)

Vantage Wire, Streetwise Reports, QualityStocks, The Street, Stock Rich, Trading Markets, BUYINS.NET, MarketBeat, StockMarketWatch, StockEgg, PinnacleDigest, CoolPennyStocks, HotOTC, Investor Guide, Penny Invest, SmallCapVoice, Stock Stars, AllPennyStocks, PennyOmega, Stock Traders Chat, OTC Picks, Money Morning, StockMister, Stockpalooza, Street Insider, FutureMoneyTrends.com, StreetInsider, The Tycoon Report and Schaeffer's reported earlier on Brickell Biotech (BBI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Boulder, Colorado and was incorporated in 2009 by Andrew D. Sklawer and Reginald L. Hardy. It operates as part of the pharmaceutical and medicine manufacturing industry in the health care sector, under the biotech and pharma sub-industry and serves consumers in the United States.

The company is party to a collaboration agreement with AnGes Inc. which entails the development of a new DNA vaccine candidate for the coronavirus. It has three firms in its corporate family and is focused on leveraging the experience of its management team to acquire, develop and commercialize innovative products that it believes can be successful in the international dermatology marketplace.

The enterprise’s pipeline comprises of new molecular entities targeting the treatment of various indications including psoriasis, cutaneous t-cell lymphoma, androgenic alopecia, allergic contact dermatitis and hyperhidrosis. Its products include BBI-6000, BBI-3000 and Sofpironium Bromide, which is currently undergoing a phase 3 clinical trial to evaluate its effectiveness in treating primary axillary hyperhidrosis.

The firm’s Sofpironium bromide formulation is currently undergoing another phase 1 clinical study which is being conducted by its development partner Kaken Pharmaceutical Co. Ltd. The study’s outcome may determine whether sofpironium bromide gel will be developed for patients in Japan who suffer from primary palmoplantar hyperhidrosis. There are currently no approved topical treatment options available, which means that its success would not only help patients with PPH but also extend the firm’s consumer reach, which would positively influence its growth.

Brickell Biotech (BBI), closed Wednesday’s trading session at $0.6614, up 6.6774%, on 2,323,004 volume. The average volume for the last 3 months is 1.271M and the stock's 52-week low/high is $0.46599999/$1.70000004.

Hut 8 Mining (HUT)

We reported earlier on Hut 8 Mining (HUT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Toronto, Canada and was incorporated in 2011, on June 9th by Andrew Kiguel. It operates as part of the software and tech services industry, in the technology sector, under the technology services sub-industry and serves consumers in North America.

The company was established through an exclusive partnership with one of the leading blockchain technology firms in the world, Bitfury. It is led by a team of industry experts who offer investors exposure to blockchain technology and blockchain processing infrastructure, together with cryptocurrency revenue from transaction fees and rewards.

The enterprise is in the business of using specialized equipment to work out complex computational problems that validate transactions on the bitcoin blockchain. Currently, the enterprise owns bitcoin mining data centers representing 165 PH/s and 24.2 MW, which are either under construction or in operation, with a pipeline of development and acquisition opportunities across North America. It also operates and owns over 50 BlockBoxes in Alberta’s Medicine Hat and more than 30 BlockBoxes in Drumheller, which is also located in Alberta. It receives bitcoin as payment for the commercial activity of bitcoin mining.

The firm recently purchased 11,090 M31S, M30S+ and M30S miners, which will be in full deployment by December 2021. This will increase the production capacity and allow the firm to double its hashrate before 2021 ends, which will also significantly increase the number of Bitcoins earned daily. The move is bound to also increase the firm’s revenue, which in turn increases its profits.

Hut 8 Mining (HUT), closed Wednesday’s trading session at $4.22, up 9.3264%, on 2,748,627 volume. The average volume for the last 3 months is 1.664M and the stock's 52-week low/high is $0.584999978/$13.00.

Wizard World, Inc. (WIZD)

QualityStocks, Wall Street Resources, StocksEarning, Wolf of Penny Stocks, Penny Picks, Epic Stock Picks, Damn Good Penny Picks, TopPennyStockMovers, MicroCapDaily, MarketBeat, Insider Financial and BeatPennyStocks reported earlier on Wizard World, Inc. (WIZD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Wizard World’s events frequently feature celebrities from movies and TV, artists and writers, and events such as premieres, gaming tournaments, panels, as well as costume contests.  The Company has its ComicConBox™. This is a subscription-based premium monthly box service. It provides fans the opportunity to receive exclusive collectibles, toys, technology, games, licensed artwork, comics, apparel, Wizard World Comic Con tickets, VIP discounts and more, delivered to their doors.   

The Company’s Comic Cons provide sales, marketing, promotions, public relations, advertising, and sponsorship opportunities for entertainment companies, toy companies, gaming companies, publishing companies, marketers, corporate sponsors, and retailers.

Wizard World Digital is the Company’s online publication. It covers new and upcoming products and talents in the pop culture world. Also, Wizard World has established a new SocialCon™ Operating Unit within Wizard World. SocialCon™ will produce a series of conventions. These will feature meet-and-greets, live performances, Q&A panels, autographs, photo opportunities and more with many of today’s most-followed social media influencers.

In addition, Wizard World has its CONtv. This is a subscription-based digital service. It brings fans their favorite films, TV series, comics, behind the scenes access to Wizard World Comic Cons, and more.

CONtv provides consumers access to thousands of hours of exclusive content highlighting an original slate of programming and a comprehensive digital catalog of over 1,200 titles. Furthermore, Wizard World has launched the new music concert series, and the Wizard World Store. 

Wizard World announced its partnership with CNLive to distribute streamed content in the People's Republic of China (PRC). This partnership with CNLive, one of only seven entities licensed to distribute content over the internet in the PRC, provides Wizard World China, a wholly-owned subsidiary of Wizard World, a multi-year right and license to program a 24/7, advertising supported channel throughout all of mainland China. This includes Macao and Hong Kong.

Wizard World, Inc. (WIZD), closed Wednesday’s trading session at $2.1, up 31.25%, on 2,723 volume. The average volume for the last 3 months is 2,003 and the stock's 52-week low/high is $0.550000011/$11.00.

HCi Viocare (VICA)

QualityStocks, ProTrader, Stock Commander, Shiznit Stocks, Penny Stock General, MicroCapDaily, OTCtipReporter, Penny Pick Finders, KingPennyStocks, Insider Financial, AwesomeStocks, HotOTC, PennyStockProphet, PennyStockScholar, StockWireNews, Small Cap Firm, Fierce Analyst, Stock Guru, Buzz Stocks, StockOnion, BullFreak, StockRunway, Profitable Trader Authority, BeatPennyStocks, Damn Good Penny Picks, Fortune Stock Alerts, Broad Street, MegaPennyStocks, OTCBB Journal, OTCMagic, Penny Picks, Penny Stock 101, PennyStockLocks, Today's Stock Tip, SmallCapGrowth, Stock Beast, StockHideout, StockRockandRoll, StocksImpossible, StockStreetWire and PennyPickAlerts reported earlier on HCi Viocare (VICA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HCi Viocare has two fully owned subsidiaries. One is HCi Viocare Technologies. The other is HCi Viocare Clinics. HCi Viocare Technologies is developing hardware solutions aiming to empower the user through providing on demand information and enhancing living quality.

HCi Viocare’s business model consists of creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and developing an extensive portfolio of proprietary hardware solutions with first in line the Flexisense™ sensor system. The clinics will provide independent and personalized quality of care for its patients. The first HCi Viocare clinic has been operating since September 2015 in Glasgow.   

The R&D center is working on a large portfolio of progressive, cutting-edge, and disruptive technologies in the Digital Health, Prosthetics, and Orthotics, Diabetes, Assistive Devices and Sports & Wellbeing fields. HCi Viocare has developed a unique sensing technology with the brand name Flexisense™.  

Flexisense™ technology is the next generation of sensing technologies for wearable devices. Flexisense™ is an inventive sensing technology. It measures pressure and shear forces. In addition, it provides on demand information wirelessly. Flexisense can be incorporated in a wide array of applications.   

The Company has developed a new application for its sensing technology Flexisense™, now for automotive tires. Flexisense™ applied to tires can monitor, in real time, tire deformation and actual traction between the tire and the ground. 

HCi Viocare Management, acknowledging the great advantages of Blockchain technology, has decided to develop its own proprietary Blockchain based system for handling the sensitive client records in its Scottish Clinics subsidiary. This team will develop a proprietary Blockchain based system for handling and storing the data produced from the medical applications of its Flexisense™ technology.

HCi Viocare (VICA), closed Wednesday’s trading session at $0.071945, up 36.2595%, on 377,830 volume. The average volume for the last 3 months is 358,406 and the stock's 52-week low/high is $0.020999999/$0.395999997.

Sino United Worldwide Consolidated Ltd. (SUIC)

MarketBeat, QualityStocks, StocksEarning and Innovative Marketing reported earlier on Sino United Worldwide Consolidated Ltd. (SUIC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Company’s primary business is in Blockchain, in 4 Sectors. These are Blockchain in Logistics and Trade; Blockchain in Vehicle and Transportation; Blockchain in Finance And Coin; and Blockchain in Medical and Healthcare. The addition of the FinTech sector to Sino United’s Blockchain services includes a complete update in which the Company will build up its own internal capabilities through actively starting a Blockchain training program, developing a 3rd generation Smart Contract Blockchain under the Sino United brand, and using these capabilities to provide a comprehensive ICO consultancy.

Sino United Worldwide Consolidated and USADAE (American Digital Asset Exchange) revealed the Joint Venture (JV) to launch the new FinTech trading platform, embarking on the first worldwide Blockchain conglomerate as a hub for innovative Blockchain technology and unique Blockchain projects. The partnership adjoins the sanctioned practices of regulated and inventive finance and exchanges and the present flourishing digital world enabled by Blockchain, Distributed Ledger and Artificial Intelligence (AI) technologies.

This Sino United-USADAE alliance offers clients security and storage services, and also trade execution for crypto, digital assets. The alliance will merge their strong trading platform technology and premium selection of digital tokens, adopting rigorous assessment utilizing the latest in proof-of-reputation algorithms and other advanced programs.

Sino United Worldwide Consolidated Ltd. (SUIC), closed Wednesday’s trading session at $1.78, up 42.4%, on 68,313 volume. The average volume for the last 3 months is 206,385 and the stock's 52-week low/high is $0.219999998/$20.00.

Apple Rush Company, Inc. (APRU)

QualityStocks, OTCPicks, MicroCapDaily, StockStreetWire, PennyStockLocks, StockRockandRoll, StockHideout, Penny Stock 101, Illuminati Stocks, Momentum Hunter, OTC Detective, Penny Stock Beats, Cash Cow Stocks, PennyTrader Publisher, Wise Alerts, ProTrader, Small Cap Academy, Stockgoodies, StockWireNews and Penny Stock Clock reported earlier on Apple Rush Company, Inc. (APRU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Company offers organic sparkling juice blended beverages, with apple juice as the base under the brand name Apple Rush. Apple Rush Company is an historical leader in the organic and natural beverage sector. Its objective is to also become the leader in the distribution of anhydrous hemp oil products nationwide.

Subsidiary APRU, LLC centers on the development and sales of all natural Apple Rush sparkling juices, and research and development (R&D) of premium hemp extracts that contain a wide array of cannabinoids and natural hemp derivatives and other active ingredients. This includes Apple Rush’s exclusive agathos active, kratom, kava, blue lotus, and ginseng.

Apple Rush Company previously announced that it delivered the second order of Element C, CBD infused beverages to North Dakota. It delivered four additional pallets to its distributor in North Dakota. The Company is finalizing its next Element C production. It is working on some final packaging designs for a number of additional products to be marketed under the brand.

Apple Rush Company also announced a letter to shareholders and an update on distribution of Element C.

Mr. Tony Torgerud, Chief Executive Officer of Apple Rush Company, said, “… APRU has produced a second batch of Element C and sales have been solid for the brand. Our product development of additional Kratom beverages and products is going smoothly and we will be announcing several new private label market entries. These new innovative beverages are first in class in both quality and effectiveness and are the stepping-stones to a strong future in the beverage industry…”

Apple Rush Company, Inc. (APRU), closed Wednesday’s trading session at $0.00545, up 29.7619%, on 6,870,702 volume. The average volume for the last 3 months is 4.766M and the stock's 52-week low/high is $0.000699999/$0.016899999.

Blockchain Industries, Inc. (BCII)

QualityStocks and TopPennyStockMovers reported earlier on Blockchain Industries, Inc. (BCII), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Company’s corporate mission is to make Blockchain Technology accessible, transparent and compliant. Blockchain Industries concentrates on long-term results - in innovation that can help governments streamline their processes, rebuild struggling economies, transform legislative practices, revolutionize healthcare and education, and ultimately better humanity.

Blockchain Industries offers early access to coveted protocols and token issuances, and considerable technical competence, an extensive industry network, and a recognized global brand. In addition, it offers top-tier experiences in finance and operations with an emphasis on compliance and risk management.

The Company’s intention is to offer investment management for blockchain-related assets; and blockchain advisory services. This includes architecting token structure and issuance, crypto-economic design, technology/engineering, consulting, generating whitepapers, software development, and marketing. Additionally, its intention is to invest in, partner with, or acquire media streams, news outlets, or other content distribution methods centered on the marketing of blockchain technologies and Digital Asset economies; partner with educational institutions to train blockchain developers; and set up cryptocurrency mining facilities.

GoChain previously announced it has partnered with IriSafe, Inc. and Blockchain Industries to develop blockchain-based identity management solutions. IriSafe is a Singapore-based joint venture (JV) between IriTech and Blockchain Industries. With guidance from Blockchain Industries, GoChain and IriSafe entered a binding joint development agreement.

GoChain takes advantage of IriTech's biometrics hardware and software development kits in collaboration with IriSafe to provide the world's first blockchain identity management solutions using ultra-secure, government-tested and certified iris-scanning technology. These solutions are constructed on GoChain's best-performing public web3-based network, giving users quicker transaction speeds and enterprise-level support that are not available with traditional identity management solutions.

Blockchain Industries, Inc. (BCII), closed Wednesday’s trading session at $0.2699, up 28.5238%, on 84,757 volume. The average volume for the last 3 months is 92,395 and the stock's 52-week low/high is $0.0722/$2.53999996.

CannaPharmaRX, Inc. (CPMD)

QualityStocks, Damn Good Penny Picks, Epic Stock Picks, StockHideout, Fierce Analyst, Make Penny Stocks Great Again, BeatPennyStocks, Penny Picks, StockWireNews, Small Cap Firm, Wolf of Penny Stocks, PennyStockLocks, Early Bird, Insider Financial, Penny Stock 101, SmallCapVoice, StockRockandRoll, TheTradingZone, TopPennyStockMovers, MicroCapDaily, Market Profit Center, ProTrader and PoliticsAndMyPortfolio reported earlier on CannaPharmaRX, Inc. (CPMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Company’s corporate mission is to produce high quality, carbon footprint efficient pharmaceutical grade medical cannabis in ultramodern, highly efficient facilities in Canada for the distribution to wholesale licensed retailers across the nation. CannaPharmaRX’s vision is the immediate national expansion via acquisitions for the continuing development of cannabis production facilities.

The Company previously completed an initial acquisition of a 48,500 square foot cannabis grow facility now under development. CannaPharmaRX is presently in discussions with other companies concerning potential acquisitions or business combinations. It is currently targeting acquisitions of companies in the final stages of obtaining cannabis licensee applications or those which are nearing revenue generation.

The Company’s Hanover facility in the Province of Ontario includes 10 acres of land and a 48.8 thousand square foot growing space to produce 9.6 thousand kg of cannabis each year. Construction is underway and the projection is to complete by September of this year. CannaPharmaRX is projected to be licensed to cultivate, granted by Health Canada October 2019, and licensed to sell, granted by Health Canada December 2019; its sales will begin immediately.

Recently, CannaPharmaRx announced it has formally executed an agreement with K&K Consulting to broaden its exposure to the medical cannabis market in Israel. Based upon current analyses, the cannabis patient numbers in Israel have reached a record high in 2020, with over 60,000 users. However, compliance issues for local producers have prevented the domestic market from supplying patients, with imports rising to avoid shortages to meet the rising demand. The company will also have access to the Israeli capital markets that may provide favorable financing for the venture.

CannaPharmaRX, Inc. (CPMD), closed Wednesday’s trading session at $0.0599, up 57.6316%, on 2,707,205 volume. The average volume for the last 3 months is 821,062 and the stock's 52-week low/high is $0.027/$2.5999999.

Meta Materials Inc. (MMAT)

Schaeffer's and QualityStocks reported earlier on Meta Materials Inc. (MMAT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Torchlight Energy Resources (NASDAQ: TRCH), an oil and gas exploration company based in Plano, Texas, has closed on its previously announced business combination with Meta Materials Inc. As a result, after market close today, Torchlight's name will be changed to Meta Materials Inc. In addition, the company’s common stock will begin trading on NASDAQ under the ticker symbol MMAT. According to the previous announcement, prior to the implementation of the reverse stock split, Meta Materials (NASDAQ: MMAT) shareholders were expected to receive 3.690 shares of Torchlight common stock in exchange for each of their shares of Metamaterial Inc., resulting in Meta Material shareholders owning approximately 75% of the resulting post-merger company. Torchlight’s current portfolio includes assets focused in West and Central Texas where targets are established plays such as the Permian Basin. Roth Capital Partners acted as financial advisor to Torchlight related to this business combination.

To view the full press release, visit https://ibn.fm/IDSax

META delivers previously unachievable performance, across a range of applications, by inventing, designing, developing and manufacturing sustainable, highly functional materials. The company’s extensive technology platform enables leading global brands to deliver breakthrough products to their customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive, and clean energy. META’s achievements have been widely recognized, including being named a Global Cleantech 100 company. For more information, visit www.Metamaterial.com

Meta Materials Inc. (MMAT), closed Wednesday’s trading session at $3.83, up 20.0627%, on 62,837,167 volume. The average volume for the last 3 months is 21.092M and the stock's 52-week low/high is $0.422199994/$21.7600002.

The QualityStocks Company Corner

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. According to the update, the study demonstrated that DehydraTECH(TM)-enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from the company’s proprietary formulation and processing, resulting in significantly increased delivery. The study also examined absorption with two other antiviral drugs previously untested by Lexaria; however, the bloodstream delivery findings were unremarkable and further work is required should the company decide to pursue additional testing with the two drugs. Lexaria will likely focus on DehydraTECH-processed colchicine and other antiviral drugs it has tested given the superior results already demonstrated. The company will summarize and provide guidance on the 2021 antiviral program to date and its planned next steps in an imminent press release. To view the full press release, visit https://ibn.fm/VLRjA

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday’s trading session at $8.44, up 28.0728%, on 53,469,454 volume. The average volume for the last 3 months is 969,448 and the stock's 52-week low/high is $3.97510004/$12.50.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

  • 2021 Sequire Blockchain Conference presentations now available on demand
  • Conference featured over 15 established and emerging companies across blockchain, cryptocurrency spaces
  • Keynote speakers included Brock Pierce, Maja Vujinovic, Saum Noursalehi, George Stella, Brittany Kaiser

SRAX (NASDAQ: SRAX), a leading financial technology company that helps public companies unlock the power of data through its Sequire SaaS platform, recently hosted the 2021 Sequire Blockchain Conference (https://ibn.fm/fTW6e), featuring over 15 leading blockchain and cryptocurrency-focused companies along with a slew of industry experts, including Brock Pierce, Maja Vujinovic, Saum Noursalehi, George Stella and Brittany Kaiser.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday’s trading session at $4.32, up 2.8571%, on 109,839 volume. The average volume for the last 3 months is 511,316 and the stock's 52-week low/high is $2.05999994/$7.28999996.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress. The recently launched EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine. Cybin has co-sponsored the study — which will be led by Dr. Anthony Back, a recognized leader in the fields of palliative care and oncology — in a strategic collaboration with the University of Washington. The study will examine treating depression, anxiety, burnout and post-traumatic stress symptoms among frontline doctors, nurses and healthcare professionals. Dr. Back is quoted in a recent article as saying, “There is tremendous potential in a collaboration between the University of Washington and Cybin to move the field forward, and this project is an incredibly valuable initial step towards a productive future.” To view the full article, visit https://ibn.fm/6ZreC

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Wednesday’s trading session at $2.83, up 2.9091%, on 453,048 volume. The average volume for the last 3 months is 590,991 and the stock's 52-week low/high is $0.493800014/$3.00999999.

Recent News

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) today announced second quarter 2021 production results from the Platosa Mine in Durango, Mexico. Among the highlights, the company reported silver equivalent ("AgEq") production of 487,009 oz. In addition, Platosa achieved its fourth consecutive quarter of over 21,000 tonnes mined and milled, with record tonnes mined (86,316) and milled (88,648) over the trailing twelve months. “Platosa delivered a fourth consecutive quarter of production at historically high productivity rates,” said Brendan Cahill, president and CEO of Excellon Resources. “We continue to see room for improvement, with our ongoing work to improve recoveries at Miguel Auza and, additionally, a sizeable inventory of ore and concentrate at quarter-end due to mill maintenance and weather conditions in late June.” To view the full press release, visit https://ibn.fm/TX8xF

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

  • Silver – 355,581 oz – $24.46
  • Lead – 2,223,465 lbs. – $0.87
  • Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Wednesday’s trading session at $2.03, up 5.1813%, on 59,419 volume. The average volume for the last 3 months is 44,145 and the stock's 52-week low/high is $1.83000004/$3.90000009.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

  • CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments
  • Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underway
  • CNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, achieved several fundamental clinical, corporate, and regulatory milestones over the last couple of months, demonstrating the company’s operational, financial, and strategic strengths and continuously de-risking its lead candidate Berubicin clinical program.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday’s trading session at $1.8, up 2.2727%, on 181,580 volume. The average volume for the last 3 months is 522,662 and the stock's 52-week low/high is $1.62/$4.46000003.

Recent News

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF)

The QualityStocks Daily Newsletter would like to spotlight Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF).

Chalice Brands (CSE: CHAL) (OTCQB: CHALF), a consumer-driven cannabis company in the medicinal and recreational marijuana market segments, is building a strong presence in Oregon. This presence allows interested Oregonians to test the cannabis cooling theory captured in a Chalice magazine article titled “Cannabis Is Cool.” The theory states that: “Cannabinoids, compounds found in cannabis, can interact with the hypothalamus and endocannabinoid system and subsequently impact temperature regulation while also occupying the vanilloid receptor family (TRPA-1, TRPM8, etc.). . . . Thanks to our interest in cannabis, we know the vanilloid receptors alter our perception of heat and pain and, therefore when also engaged by cannabinoids, may numb our sensation of heat and feeling hot.” The article came as the West was experiencing record heat levels, with temperatures topping 100 degrees in California, Oregon, Arizona, Nevada and Utah. While Chalice calls for people to be reasonable and intelligent adults by making sure they drink water and finding shade or air conditioning, the company also offers this suggestion: “Beat the heat this summer with temperature-fighting cannabis. . . . If this is another excuse to consume a little bit more cannabis, we’ll take it!” To view the full article, visit: https://cnw.fm/jC82z

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) is a premier consumer-driven cannabis company powered by the Chalice retail and consumer brands. Chalice Brands takes a diversified approach to growth through innovation, strategic partnerships and retail expansion, as well as a brand portfolio focusing on health and wellness. The company features best in class retail cannabis experiences backed by cultivation, processing and developing wholesale distribution. With over 160 employees, Chalice Brands is one of the largest cannabis operators in Oregon. The company holds licensing in Oregon, as well as partnerships for manufacturing and distribution in California. Its current product portfolio includes recognizable brands such as Chalice(TM), Elysium Fields(TM), GOLDEN(TM), Jackpot(TM) and RXO(TM).

Brands

Chalice Brands offers an innovative product line that addresses current market needs and looks forward to meet emerging trends. The company’s goal is to offer something for everyone through the wholesale and retail marketplaces. Its current product offerings include:

Chalice(TM)
The Chalice Farms(TM) brand is focused on how cannabis enhances lives and ignites purpose. By offering the highest quality of cannabis in an array of flower, extracts, oils, edibles and full-body care products, the brand provides full efficacy in both the retail and wholesale markets. The Chalice Farms team has over 100 years of combined cannabis experience and continues to be an industry leader for both medical and recreational cannabis use – providing state-of-the-art farming practices, excellent retail and complete product innovation.

Elysium Fields(TM)
Elysium Fields(TM) is a “soil-to-oil” craft cannabis brand intended for cannabis connoisseurs who want the highest quality THC and boldest terpene flavors. Made from small-batch live resin, Elysium Fields creates an experience described as a remarkable entourage effect. The C-Cell cartridge has a 30% strain specific HTE with a 70% high THC distillate. The resin is created from a sustainable, organic garden flower that is flash-frozen upon harvest to preserve the terpenes for a heavenly experience.

RXO(TM)
RXO(TM) features Chalice Farms’ purest and most versatile Rick Simpson Oil products. RXO was developed by the Steele brothers in collaboration with medical professionals and is a potent, strain-specific Ethanol Hash Oil (EHO) purified through a proprietary process. Through this process, various consumption methods can be accommodated, including edible, topical, sublingual and smoking (shatter and vape).

GOLDEN(TM)
GOLDEN(TM) offers a wide variety of craft cannabis products for a diverse population of cannabis users. Sourced from the finest raw materials from local growers, GOLDEN products are high-quality and innovative. Premium cannabis distillate vaporizer cartridges and fruit chew edibles made from organic ingredients are made using the most flavorful terpenes for enhanced health, wellness and enjoyment. Products are distributed online and through Chalice Farms or other dispensary partners.

Jackpot(TM)
Jackpot(TM) products offer a powerful combination of flavor and potency. With 70% THC content in each cartridge, Jackpot adds full-spectrum cannabinoids and flavorful infused terpenes in short-run limited strains for on-the-go fun seekers. The quality hardware of the cartridges makes them easily recyclable and guarantees to produce a large volume draw each time.

Financial Results

On May 25, 2021, Chalice Brands announced its financial results for the first quarter of 2021. Among the highlights, the company reported:

  • Record quarterly revenues from continuing operations of $5.5 million, marking an 18% year-over-year increase compared to $4.7 million for the same period in 2020.
  • Gross profit for the three-month period of $2.5 million on 45% gross margin, compared to $1.7 million in gross profit on a 37% gross margin in 2020.
  • Its second consecutive quarter of positive adjusted EBITDA, recording approximately $370,000, or 7%, and continuing to demonstrate that the company’s Oregon operations are capable of covering corporate overhead costs.

In announcing the results, Jeff Yapp, CEO of Chalice Brands, stated, “Continued profitable operations and accretive acquisitions should set us up for a record breaking second half of 2021. We continue to look forward to favorable federal regulation changes while we grow Fifth & Root to showcase our brand portfolio nationally. Our team is energized and focused on growth as we remain disciplined in our allocation of capital.”

Cannabis Market Outlook

In 2020, the legal cannabis market was valued at approximately $23 billion, and it is expected to top $73.6 billion in revenue by 2027, growing at a CAGR of 18.1% during the forecast period (https://ibn.fm/LdkhG). One of the biggest factors driving the cannabis market’s growth is legalization around the world.

As cannabis sales generally increased during the pandemic, Chalice Brands achieved record financials for Q4 2020, reporting quarterly revenue of $5.5 million, a year-over-year increase of 53%. The fourth quarter of 2020 also marked the company’s first quarter with positive adjusted EBITDA, reporting approximately $342,000 (https://ibn.fm/QMqrF).

Chalice Brands is uniquely positioned to capitalize on the growth of both the medicinal and recreational marijuana market segments through a rich product offering that successfully addresses current consumer needs.

Management Team

Jeff Yapp is the CEO and President of Chalice Brands Ltd. He has created a culture at Chalice Brands that operates under his mantra of ‘Crawl, Walk, Run’. He is an accomplished entrepreneur and corporate executive who has built a successful career through his ability to recognize opportunity, even when it isn’t obvious. Mr. Yapp has an extensive background in retail, marketing and entertainment. In the past, he has been committed to bringing innovation to Fortune 25 companies such as Microsoft, Kraft Foods, PepsiCo and more. As a strategic partner for Microsoft, he is an integral driver of growth for online and retail operations. He graduated with honors from the University of Michigan, majoring in Business Administration. He also graduated with honors from JL Kellogg School of Management at Northwestern University.

John Varghese is the Executive Chair of Chalice Brands and is responsible for all capital markets initiatives at the company. His background is in mergers and acquisitions, investing, operations and capital markets, with professional experience that ranges from private equity, venture capital and investment banking to senior management positions and director roles in both private and public companies. He has served on over 20 boards, acting as the chairman of six of them.

Andrew Marchington is the company’s CFO. His public accounting career experience includes time with start-up, high-growth and enterprise-level organizations, including five years of prior cannabis industry experience. He has a rich understanding of the priorities and best practices within accounting, finance and management. Mr. Marchington’s past experience includes time with companies like Deloitte, Moss Adams, Cambia Health Solutions and C21 Investments.

John Ford, Chalice Brands’ Chief Revenue Officer and VP of Retail, is a seasoned and dynamic retail leader with extensive experience in the retail industry who has led the launch of major retail brands such as Apple and Microsoft in China and Australia. His goal is to help retailers transition their businesses to modern experiential locations where customers can engage with products and brands in new ways. At Apple, Mr. Ford was the only field expat sent to launch Apple Retail in China. He set several records for Apple while in China, not just in sales but also in inventory management and employee turnover. Mr. Ford left Apple to lead Microsoft’s international retail expansion, where he also managed its e-commerce presence.

Chalice Brands Ltd. (CHALF), closed Wednesday’s trading session at $0.89, up 2.2401%, on 16,049 volume. The average volume for the last 3 months is 67,080 and the stock's 52-week low/high is $0.0502/$2.02629995.

Recent News

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

  • Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced its plans to conduct a phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. According to the update, the open-label trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia. The treatment is designed to leverage the neuroplasticity benefits of psilocybin to target nociplastic pain originating in the central nervous system. To view the full press release, visit https://ibn.fm/cCSc2
  • Prior studies have discovered that young individuals who experience discrimination or teasing about their weight have higher rates of eating disorders, self-harm, depression and social isolation. However, these studies have primarily focused on high-income and white participants, which makes it unclear whether these findings apply to other groups as well. This is why researchers from the School of Public Health at the University of Minnesota in Minneapolis conducted a study to examine the link between eating disorders and weight stigma in a socioeconomically and racially/ethnically diverse sample of more than 1,500 young individuals in the United States. To help people who are afflicted by eating disorders, a number of companies, including Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), are developing a new variety of medications, such as those which are psychedelics based, to give sufferers better outcomes.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

  • Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
  • Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
  • Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Wednesday’s trading session at $0.42, up 5.2975%, on 111,635 volume. The average volume for the last 3 months is 84,305 and the stock's 52-week low/high is $0.370000004/$1.03999996.

Recent News

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis- and hemp-branded products company, added availability of its popular — and limited edition — PLUS Hash Gummies. The company ordered a second batch of the gummies, which were created in partnership with Biscotti Brands, a premium hash brand. According to the announcement, the PLUS Hash Gummies are flavored with orange blossom and infused with cold water hash extracted from the Miracle Alien Cookies (“MAC”) flower, a hybrid strain renowned for its relaxing and uplifting effects. The formulation of the gummies was designed to bring consumers as close to the plant as possible, said the company; each gummy contains 10mg of THC. To view the full press release, visit https://ibn.fm/QNdAL

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Wednesday’s trading session at $0.344, up 18.6616%, on 84,759 volume. The average volume for the last 3 months is 100,640 and the stock's 52-week low/high is $0.265599995/$1.14999997.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based growth stage company committed to providing commercially viable and sustainable energy solutions, announced that it has been approved to trade its common shares on the OTCQB(R) Venture Marketplace under the symbol NHHHF, effective today. “Trading our shares on the OTCQB Venture is an important milestone for FuelPositive because it increases our investor audience significantly, providing us with greater visibility and liquidity,” said Ian Clifford, FuelPositive CEO. “We believe the exciting promise of our carbon-free ammonia (‘NH3’) and its role in significantly reducing greenhouse gases across multiple sectors will resonate with institutional and retail investors within the U.S. investor community, opening up enhanced opportunities for engagement.” To view the full press release, visit https://ibn.fm/UyREO

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Wednesday’s trading session at $0.183, up 10.241%, on 1,454,969 volume. The average volume for the last 3 months is 768,269 and the stock's 52-week low/high is $0.0125/$0.326000005.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

  • The new version of the Fan Pass platform (v2.0) for mobile and desktop is scheduled for release one year after its debut, with new and improved offerings outlined in a new corporate presentation
  • Artists and fans both benefit from the updated version, gaining an easy-to-use dashboard that tracks ticket and merchandise sales (for artists) and special access into the lives of the artists (for fans)
  • Friendable estimates that if three celebrity partners with 10 million followers each marketed the Fan Pass platform and 1% of those followers subscribed, that would bring 300,000 new subscribers to the artist streaming platform
  • A subscription to the Fan Pass platform is $2.99 all-access, and additional PPV events are priced individually on a case-by-case basis

With the first anniversary of Friendable’s (OTC: FDBL)  flagship offering, the Fan Pass platform, drawing near, the company reports a key milestone – 5,000 new sign-ups for the artist streaming platform. The Fan Pass platform was created to give fans exclusive access to the lives of their favorite artists, and artists a virtual stage to earn revenue, engage fans, and above all else, perform.

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Wednesday’s trading session at $0.0093, up 1.6393%, on 777,947 volume. The average volume for the last 3 months is 2.664M and the stock's 52-week low/high is $0.007799999/$0.114950001.

Recent News

BAND Royalty

The QualityStocks Daily Newsletter would like to spotlight BAND Royalty.

BAND Royalty, an enterprising music technology company, has emerged as a revolutionary new player in the non-fungible token (“NFT”) market. The company has applied its experience in music industry investments to the digital art collectibles arena in order to create a new type of best-of-both-worlds product. The product combines NFT art with a potential DeFi project that allows people to share in music royalties. BAND Royalty’s first series of 3,000 NFTs made available for sale to the public on May 15 includes royalties from music catalog selections featuring artists such as Justin Timberlake, Jay-Z, Beyonce and Timbaland. According to a recent article, BAND co-founder Noble Drakoln said: “It’s a secret hidden world of investing. People don’t know they can buy performance royalties of major acts. . . . And that these rights are always floating out there for people to acquire them on various songs that these artists performed on. We listen to all these people on radio and we don’t know that there’s actually an income stream being developed.” To view the full article, visit https://ibn.fm/Y3CL4

BAND Royalty (operated by Singapore-based LIBERTY IS PTE LTD) is the leading innovator of music-focused NFTs. BAND is an entertainment technology-driven firm focused on the distribution of non-fungible tokens (NFTs) that allow fans to earn royalties from top songs and artists worldwide.

BAND Royalty lets fans take their enjoyment of music to the next level by offering blockchain-secured BAND NFTs that enable holders to earn crypto from some of the world’s most popular songs. This unique opportunity allows individuals to share in income streams each time a song in the BAND Royalty music catalog is performed.

BAND’s royalty pools leverage a performance music catalog featuring tracks from some of the biggest names in music, including Beyonce, Jay-Z, Justin Timberlake, Cher, will.i.am, Timbaland, Missy Elliott and Rihanna.

BAND Royalty NFTs

BAND NFTs, hosted on the ethereum blockchain, are a special type of NFT that can be staked into any one of three BAND Royalty Music Pools to receive a portion of all royalty streaming income from each track, for each royalty pool category. The BAND ecosystem is supported by multiple types of transactions:

  • Trading BAND Royalty NFTs – The first ever issuance of BAND NFTs is being offered to the public. Owners of the BAND NFTs will be able to trade them on the largest NFT marketplace, OpenSea, where the BAND NFTs are being launched on May 5, 2021.
  • Music Royalty Pools – These blockchain BAND NFTs have a special DeFi (decentralized finance) utility. Holders of BAND NFTs have the option to stake their tokens for a period of 90 days to five years, with longer stakes receiving proportionally increased amounts of the royalties share. Holders have the option to trade their BAND NFTs or stake them in one of three special music catalog pools that provide access to BAND music royalties. The three types of music pools available for staking are print music, mechanical/public performance and synchronization.

Through staking BAND NFTs, the holder can earn crypto from both BAND NFT trades on the OpenSea NFT marketplace and from the BAND music catalog royalty revenue.

The company intends to sell three more series of BAND NFTs, with 3,000 NFTs in each series. This strategy would cap the supply of BAND NFTs at a maximum of 12,000 units. As these NFTs are staked to capitalize on royalty opportunities, the supply of BAND NFTs available for trade is expected to be reduced, which the company then expects would increase the value of the BAND NFTs moving forward.

Market Opportunity

The market for NFTs has exploded in 2021, driven by rising media coverage and mainstream awareness. A well-known example is the first tweet by Twitter CEO Jack Dorsey, which was sold as an NFT for the equivalent of $2.9 million in March. This growth has been particularly apparent for art-focused NFTs, spearheaded by digital artist Beeple, who sold an NFT series titled “Everyday: The First 5000 Days” for over $69 million at auction during that same month.

The performance of the NFT space hasn’t just been confined to those big-ticket items. OpenSea, the largest NFT marketplace, reported monthly sales of over $95 million in February 2021 alone, up from $8 million the previous month. In total, over $400 million in NFT trading had taken place on the ethereum blockchain as of early April, with nearly half taking place from February to March 2021.

As Reuters reports, enthusiasts view NFTs as the future of ownership, and they solve the problem of monetization for digital artwork. Importantly, the report notes that “NFTs could also transform music.” The industry seems to agree.

In March 2020, Kings of Leon released their latest album, When You See Yourself, in the form of an NFT – a milestone in the history of the entertainment industry.

BAND Royalty is uniquely positioned to capitalize on the shifting landscape surrounding digital ownership as it continues to roll out its series of BAND NFTs in the months to come.

BAND Royalty Founders

The name BAND is the combination of the founders’ initials, Barnaby Andersun and Noble Drakoln.

Barnaby Andersun (BA) has spent years developing blockchain and cryptocurrency solutions, acting as CEO of BlockAlchemy, a blockchain, ecommerce and digital design consulting firm. Being involved in all aspects of web technologies since their conception in the early nineties has made Mr. Andersun a true pioneer in web development, ecommerce, branding, online marketing and blockchain. A sought-after international speaker, Mr. Andersun has been invited to speak on cryptocurrencies at Harvard and World Economic Forum, Davos, where he coordinated a blockchain digital asset conference, as well as Stanford University.

Noble Drakoln (ND) has been an avid music royalty investor for decades. He is also CEO of WarePlay Games Inc., a mobile AR/XR game design and development studio. Having started out as a futures and commodities broker at the age of 19 trading the E-mini S&P, gold futures contracts and treasury bond strips, he went on to author the Wiley & Sons-published best-selling books ‘Winning the Trading Game’ and ‘Trade Like a Pro’. Along with being a tech investor, financial author and sought-after speaker, Mr. Drakoln has been a contributing writer to Forbes and Futures Magazine, and a radio and T.V. financial commentator on Bloomberg and Fox Business News.

BAND Royalty is operated by Singapore based LIBERTY IS PTE. LTD, located at 23 New Industrial Road #04-09 Solstice Business Center Singapore 536209.


Recent News

chart

Hero Technologies Inc. (OTC: HENC)

The QualityStocks Daily Newsletter would like to spotlight Hero Technologies Inc. (OTC: HENC).

Hero Technologies (OTC: HENC) has a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal conditions in greenhouses to enhance photosynthesis and produce large flowering plants. Thus, the trend toward greenhouse cultivation is welcome news for HENC. A recent article reads, “According to a recent five-year study of the cannabis industry, greenhouse production is a leading choice for cannabis cultivation companies (https://cnw.fm/R9t7G). The report, published by ‘Cannabis Business Times,’ reaffirms the business strategy of Hero Technologies.” To view the full article, visit https://cnw.fm/W3w1X

Hero Technologies Inc. (OTC: HENC) is a cannabis company with a vertically integrated business model and plan that includes cannabis genetic engineering, farmland for medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, retail operations and dispensaries that make the organization a multi-state operator (MSO).

The company was founded in 2004 and is headquartered in Dover, Delaware.

Portfolio

The company holds the majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation firm focused on providing optimal conditions to enhance photosynthesis and cultivation. Hero Technologies is planning expansion in cultivation and dispensary operations in Colorado through wholly owned subsidiary Mile High Green LLC, while expansion in Massachusetts is planned through another wholly owned subsidiary, MassCannabis LLC.

Hero Technologies also owns and operates HighlyRelaxing.com under Highly Relaxing LLC and recently acquired the assets of V Brokers LLC, now operating as Veteran Hemp Co. at VeteranHempCo.com.

BlackBox Systems and Technologies LLC

BlackBox Systems and Technologies LLC markets a proprietary cannabis aeroponic cultivation system designed for the large-scale production of top-shelf cannabis products. BlackBox offers the optimal conditions to enhance photosynthesis and promote the cultivation of large flowering plants. The system’s dry room, process room and secure storage were designed for precise control through each phase of the cannabis lifecycle. Weekly harvests are achieved using 13 separate BlackBox systems in independent modules.

The system provides a series of key benefits, including:

  • High-pressure nutrient delivery, with no nutrient or PH deficiencies
  • Sterile, 100% nutrient solution
  • Drain to Waste (no reuse of wastewater)
  • Low water usage (1 gallon per plant per day)
  • Constant PH and EC in reservoirs
  • Modular design (1 to 100 pods in any configuration)
  • Innovative proprietary engineering
  • Minimal cleanup
  • Media-less growing, suspended in the air, with no media waste
  • No pesticides

Highly Relaxing LLC

Highly Relaxing LLC is an emerging Henderson, Nevada-based operation dedicated to providing customers with honestly labeled, high-quality hemp-derived CBD products. Its current offerings include a topical CBD cream that provides localized relief from potential discomfort.

Veteran Hemp Co.

Veteran Hemp Co.’s mission is to provide a quality, consistent and delicious product for Americans looking to enjoy the hemp smoking experience. Its product is brought in by only the finest farming operations delivering the best genetics. Veteran Hemp Co. has its own custom harvest plans, drying facilities and all of the logistics that fall between. Veteran Hemp Co. prides itself on being a veteran-approved company.

Market Outlook

The global legal cannabis market is anticipated to reach $84 billion by 2028, expanding at a CAGR of 14.3% from 2021 to 2028. The driving factor for this forecast expansion is the increasingly widespread legalization of cannabis for medical and recreational use. Recreational use accounted for 60.3% of industry revenue in 2020.

North America provided the largest revenue share in the cannabis market, accounting for 91.1% of the global market in 2020. Due to the early legalization of medical and recreational cannabis in the region, the customer pool has increased exponentially (https://nnw.fm/snpHh).

The global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a CAGR of 21.2% and reach $13.4 billion by 2028. North America is considered the most progressive region for cannabis and its derived products, with the highest number of CBD companies being based on the continent. The B2B (business to business) segment dominates the CBD industry, accounting for the largest revenue share at 59.6% in 2020 (https://nnw.fm/cGxXQ).

With its vertically integrated business model and development into a multi-state operator across multiple sectors of the cannabis industry, Hero Technologies is uniquely positioned to capitalize on the fast-growing market and the growing number of opportunities emerging as a result of legalization and increased popularity among consumers.

Management Team

Gina Serkasevich, CPA, CMA, is the Chief Executive Officer, Treasurer and Secretary of the Hero Technologies. She previously worked for Holloman Corporation as its Director of Finance beginning in June 2012 and was appointed Chief Financial Officer of Holloman Energy Corporation in August 2014. She has more than 30 years of domestic and international corporate accounting and finance experience. She served as U.S. Controller for EFLO Energy Inc., a company focused on the acquisition, exploration and development of oil and gas assets in North America. Prior to 2012, Ms. Serkasevich worked in the oil and gas tanker transportation industry as a Regional Financial Manager for AET Inc. Limited (2011-2012), as a Financial Consultant for OSG Ship Management Inc. (2009-2011) and as a Financial Controller/CFO for Stena Bulk LLC (1998-2008). During her 11-year tenure at Stena Bulk LLC, she established the financial, accounting and reporting requirements for its new joint ventures and tanker pools with Sonanagol USA and held the Company Secretary position on both of those companies’ boards of directors.

Dan McCarthy is the company’s Corporate Development Manager. He has spent more than 12 years in the institutional investment community, holding various investment banking and private equity executive roles. Thus far, he has been a part of over $1 billion in transactional value ranging from debt and equity to acquisitions and diversities throughout his career. Mr. McCarthy’s most recent role was Managing Director at Petro Capital, a Dallas-based private equity and investment bank. He began his career working for a private international consulting firm based in Washington, D.C., helping corporations and funds expand into non-G7 countries utilizing World Bank financing. He is also a graduate of the University of Kansas School of Business and completed the Mergers and Acquisitions program at the New York Institute of Finance.

James Rowland is Hero Technologies’ Marketing Advisor and an expert in marketing and e-commerce. He has held many high-level marketing and business-related roles. He is the Founder and current CEO of PerfectCheckout.com and the current Business Development Specialist at Fulfillment.com. Mr. Rowland has held multiple high-level positions throughout his career, which have provided him with the experience needed to bring success-backed marketing leadership skills to his current role with the company.

Hero Technologies Inc. (HENC), closed Wednesday’s trading session at $0.072, off by 0.552486%, on 38,698 volume. The average volume for the last 3 months is 237,742 and the stock's 52-week low/high is $0.0236/$0.317400008.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading